Artikel Jurnal

Boosting Antioxidant Defense: The Effect of Astaxantin on Superoxidase Dismutase and Malondialdehyde Reduction in Patients with Head and Neck Cancer Receiving Cisplatin Chemotherapy 2024

---

Background: Superoxide dismutase (SOD) can be decreased and malondialdehyde (MDA) can be increased
in patients with head and neck cancer (HNC) as a result of reactive oxygen species (ROS) brought on by cisplatin.
Astaxanthin is one of the external antioxidants required to combat ROS by raising SOD and lowering MDA. The purpose
of this study is to demonstrate that astaxanthin can raise SOD and lower MDA in patients with HNC caused by cisplatin.
Methods: 42 research subjects were randomly assigned to two groups in a double-blind, randomized controlled trial
pre-post test design. Astaxanthin 4 mg BID was administered to the treatment group, whereas a single dosage of 500
mg of vitamin C and 250 mg of vitamin E IU was given to the control group. According to the Mann Whitney test, if
p < 0.05, there is a significant difference in the delta of the decrease in SOD and MDA levels between the astaxanthin
and vitamin C & E groups. Results: There were 42 research subjects, with a mean age of 48.2 years, a 2:1 male to
female ratio, 23 (54.8%) with nasopharyngeal cancer, 32 (76.2%) with stage IV, 14 (33.3%) with cycle IV, 24 (57.1%)
with paclitaxel-Cisplatin, 31 (73.8%) with Eastern Cooperative Oncological Group (ECOG) I, and 31 (73.8%) with
Normal Body Mass Index. While there was a substantial drop in MDA (p=0.000), there was no significant difference in
the delta reduction in SOD (p=0.443). Conclusion: Patients with HNC who receive cisplatin chemotherapy can have
an increase in SOD and a decrease in MDA after receiving astaxanthin for 21 days.
Keywords: Astaxanthin- SOD- MDA- HNC- cisplatin- ROS

---

Availability

Detail Information

Series Title

-

Call Number

616.99 YUS b

Publisher

Iran : Asian Pacific Organization for Cancer Prevention., 2024

Collation

-

Language

English

ISBN/ISSN

-

Classification

616.99

Content Type

text

Media Type

-

Carrier Type

-

Edition

TAHUN 2024

Subject(s)

Head and Neck Neoplasms
astaxanthine
Cisplatin

Specific Detail Info

https://doi.org/10.31557/APJCP.2024.25.10.3741

Statement of Responsibility

Yusuf Aminullah

Viewer

8

Other Information

Tanggal Pelaksanaan - Dari

2024-10-29

Tanggal Pelaksanaan - Sampai

2024-10-29

Akreditasi

Tidak

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment